The New Era of Epithelium-targeted Drug Development

DOI Web Site Web Site PubMed 31 References

Bibliographic Information

Other Title
  • 上皮を標的とした創薬研究のらせん的発展
  • Symposium Review 上皮を標的とした創薬研究のらせん的発展
  • Symposium Review ジョウヒ オ ヒョウテキ ト シタ ソウヤク ケンキュウ ノ ラセン テキ ハッテン

Search this article

Abstract

  Epithelium plays pivotal roles in biological barrier separating the inside of body and the outside environment. Ninety percent of malignant tumors are derived from epithelium. Most pathological microorganisms invade into the body from mucosal epithelium. Thus, epithelium is potential targets for drug development. Claudins (CLs), a family of tetra-transmembrane protein consisting of over 20 members, are structural and functional components of tight junction-seals in epithelium. Modulation of CL-seals enhanced mucosal absorption of drugs. CLs are often over-expressed in malignant tumors. CL-4 expression is increased in the epithelial cells covering the mucosal immune tissues. Very recently, CLs are also expected to be targets for traumatic brain injury and regenerative therapy. In this review, we overview the past, the present and the future of CLs-targeted drug development.<br>

Journal

  • YAKUGAKU ZASSHI

    YAKUGAKU ZASSHI 134 (5), 641-645, 2014-05-01

    The Pharmaceutical Society of Japan

References(31)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top